Cancer Therapeutic Targeting Using Mutant–p53-Specific siRNAs

Oncogene - United Kingdom
doi 10.1038/s41388-018-0652-y
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Therapeutic Targeting of the P53 Pathway in Cancer Stem Cells

Expert Opinion on Therapeutic Targets
Molecular MedicineDrug DiscoveryClinical BiochemistryPharmacology
2012English

Therapeutic Targeting of Isocitrate Dehydrogenase Mutant AML

Expert Opinion on Investigational Drugs
MedicinePharmacology
2017English

Cancer Therapeutic Approach Based on Conformational Stabilization of Mutant P53 Protein by Small Peptides

Oncotarget
Oncology
2016English

Targeting Mutant AKT in Cancer

Cancer Discovery
Oncology
2015English

Therapeutic Approaches Targeting Nucleolus in Cancer

Cells
2019English

Mutant Proteins as Cancer-Specific Biomarkers

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2011English

A Novel Mutant P53 Binding Partner BAG5 Stabilizes Mutant P53 and Promotes Mutant P53 GOFs in Tumorigenesis

Cell Discovery
BiochemistryGeneticsCell BiologyMolecular Biology
2016English

Targeting P53-Mdm2-MDMX Loop for Cancer Therapy

Sub-Cellular Biochemistry
BiochemistryCancer ResearchCell BiologyMolecular Biology
2014English

The Role of Mutant P53 Protein in Breast Cancer.

1997English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy